Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration.

Abstract

We studied the antibody response to pneumococcal serotypes 3 and 14 after pneumococcal polysaccharide vaccine was administered to 41 children with renal disease. One month after vaccination, 76% and 61% of patients achieved at least a twofold titer rise to serotypes 3 and 14, respectively; this finding was comparable to historic control values. One year after vaccination, the majority of patients retained protective antibody levels. Achieving a titer > or = 1.0 microgram/ml IgG at 1 month was highly predictive of retaining a protective antibody level > or = 0.15 microgram/ml at 1 year.

Cite this paper

@article{Furth1996PneumococcalPV, title={Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration.}, author={Susan Furth and Alicia M. Neu and Barbara W. Case and Howard M. Lederman and Margaret M. Steinhoff and Barbara A. Fivush}, journal={The Journal of pediatrics}, year={1996}, volume={128 1}, pages={99-101} }